aluates Reports

$ 0.0

Automative

Global Biopharmaceutical CDMO Market Research Report 2026

Published Date: 2026-04-24

Report Code: QYRE-Auto-33P15413

Global Biopharmaceutical CDMO Market Research Report 2023

BUY CHAPTERS

Global Biopharmaceutical CDMO Market Research Report 2026

Code: QYRE-Auto-33P15413

Report

2026-04-24

Pages:121

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Recipharm

Samsung Biologics

Siegfried

Aenova Group

GenScript

ProBioGen

KBI Biopharma

3P Biopharmaceuticals

Rentschler Biopharma

Northway Biotech

Boehringer Ingelheim

Lonza

Catalent

FUJIFILM Diosynth Biotechnologies

WuXi AppTech

Thermo Fisher Scientific

AGC Biologics

Biopharmaceutical CDMO Market Size

The global Biopharmaceutical CDMO market was valued at US$ 31490 million in 2025 and is anticipated to reach US$ 73860 million by 2032, at a CAGR of 13.1% from 2026 to 2032.

Biopharmaceutical CDMO Market

Biopharmaceutical Contract Development and Manufacturing Organizations (CDMOs) are companies that provide comprehensive services for the development and manufacturing of biopharmaceutical products. These organizations play a crucial role in the biopharmaceutical industry by offering a range of services to biotech and pharmaceutical companies, allowing them to outsource various stages of the drug development and manufacturing process.

The core global biopharmaceutical CDMO manufacturers include Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim and WuXi AppTech. The top three manufacturers account for approximately 37% of the global share. North America is the world's largest market, accounting for nearly 32% of the market share.

In terms of product type, antibodies occupy a dominant position, accounting for 36% of the market share. At the same time, in terms of application, large companies are the largest application field, accounting for 58%.

This report delivers a comprehensive overview of the global Biopharmaceutical CDMO market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Biopharmaceutical CDMO. The Biopharmaceutical CDMO market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Biopharmaceutical CDMO market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Biopharmaceutical CDMO manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Biopharmaceutical CDMO Market Report

Report Metric	Details
Report Name	Biopharmaceutical CDMO Market
Accounted market size in 2025	US$ 31490 million
Forecasted market size in 2032	US$ 73860 million
CAGR	13.1%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Cell and Gene Therapies Antibodies Vaccines Other
Segment by Application	SMBs Large Companies
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, WuXi AppTech, Recipharm, Thermo Fisher Scientific, AGC Biologics, Rentschler Biopharma, KBI Biopharma, Siegfried, Aenova Group, GenScript, ProBioGen, Northway Biotech, 3P Biopharmaceuticals
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Biopharmaceutical CDMO companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is Biopharmaceutical CDMO Market growing?

Ans: The Biopharmaceutical CDMO Market witnessing a CAGR of 13.1% during the forecast period 2026-2032.

What is the Biopharmaceutical CDMO Market size in 2032?

Ans: The Biopharmaceutical CDMO Market size in 2032 will be US$ 73860 million.

What is the market share of major companies in Biopharmaceutical CDMO Market?

Ans: The top three manufacturers account for approximately 37% of the global share.

What is the Biopharmaceutical CDMO Market share by region?

Ans: North America is the world's largest market, accounting for nearly 32% of the market share.

What is the Biopharmaceutical CDMO Market share by type?

Ans: In terms of product type, antibodies occupy a dominant position, accounting for 36% of the market share.

Who are the main players in the Biopharmaceutical CDMO Market report?

Ans: The main players in the Biopharmaceutical CDMO Market are Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, WuXi AppTech, Recipharm, Thermo Fisher Scientific, AGC Biologics, Rentschler Biopharma, KBI Biopharma, Siegfried, Aenova Group, GenScript, ProBioGen, Northway Biotech, 3P Biopharmaceuticals

What are the Application segmentation covered in the Biopharmaceutical CDMO Market report?

Ans: The Applications covered in the Biopharmaceutical CDMO Market report are SMBs, Large Companies

What are the Type segmentation covered in the Biopharmaceutical CDMO Market report?

Ans: The Types covered in the Biopharmaceutical CDMO Market report are Cell and Gene Therapies, Antibodies, Vaccines, Other

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Biopharmaceutical CDMO Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Cell and Gene Therapies

1.2.3 Antibodies

1.2.4 Vaccines

1.2.5 Other

1.3 Market by Application

1.3.1 Global Biopharmaceutical CDMO Market Growth by Application: 2021 vs 2025 vs 2032

1.3.2 SMBs

1.3.3 Large Companies

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Biopharmaceutical CDMO Market Perspective (2021–2032)

2.2 Global Biopharmaceutical CDMO Growth Trends by Region

2.2.1 Global Biopharmaceutical CDMO Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Biopharmaceutical CDMO Historic Market Size by Region (2021–2026)

2.2.3 Biopharmaceutical CDMO Forecasted Market Size by Region (2027–2032)

2.3 Biopharmaceutical CDMO Market Dynamics

2.3.1 Biopharmaceutical CDMO Industry Trends

2.3.2 Biopharmaceutical CDMO Market Drivers

2.3.3 Biopharmaceutical CDMO Market Challenges

2.3.4 Biopharmaceutical CDMO Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Biopharmaceutical CDMO Players by Revenue

3.1.1 Global Top Biopharmaceutical CDMO Players by Revenue (2021–2026)

3.1.2 Global Biopharmaceutical CDMO Revenue Market Share by Players (2021–2026)

3.2 Global Top Biopharmaceutical CDMO Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Biopharmaceutical CDMO Revenue

3.4 Global Biopharmaceutical CDMO Market Concentration Ratio

3.4.1 Global Biopharmaceutical CDMO Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Biopharmaceutical CDMO Revenue in 2025

3.5 Global Key Players of Biopharmaceutical CDMO Head Offices and Areas Served

3.6 Global Key Players of Biopharmaceutical CDMO, Products and Applications

3.7 Global Key Players of Biopharmaceutical CDMO, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 Biopharmaceutical CDMO Breakdown Data by Type

4.1 Global Biopharmaceutical CDMO Historic Market Size by Type (2021–2026)

4.2 Global Biopharmaceutical CDMO Forecasted Market Size by Type (2027–2032)

5 Biopharmaceutical CDMO Breakdown Data by Application

5.1 Global Biopharmaceutical CDMO Historic Market Size by Application (2021–2026)

5.2 Global Biopharmaceutical CDMO Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America Biopharmaceutical CDMO Market Size (2021–2032)

6.2 North America Biopharmaceutical CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Biopharmaceutical CDMO Market Size by Country (2021–2026)

6.4 North America Biopharmaceutical CDMO Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Biopharmaceutical CDMO Market Size (2021–2032)

7.2 Europe Biopharmaceutical CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Biopharmaceutical CDMO Market Size by Country (2021–2026)

7.4 Europe Biopharmaceutical CDMO Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Biopharmaceutical CDMO Market Size (2021–2032)

8.2 Asia-Pacific Biopharmaceutical CDMO Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Biopharmaceutical CDMO Market Size by Region (2021–2026)

8.4 Asia-Pacific Biopharmaceutical CDMO Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Biopharmaceutical CDMO Market Size (2021–2032)

9.2 Latin America Biopharmaceutical CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Biopharmaceutical CDMO Market Size by Country (2021–2026)

9.4 Latin America Biopharmaceutical CDMO Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Biopharmaceutical CDMO Market Size (2021–2032)

10.2 Middle East & Africa Biopharmaceutical CDMO Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Biopharmaceutical CDMO Market Size by Country (2021–2026)

10.4 Middle East & Africa Biopharmaceutical CDMO Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Lonza

11.1.1 Lonza Company Details

11.1.2 Lonza Business Overview

11.1.3 Lonza Biopharmaceutical CDMO Introduction

11.1.4 Lonza Revenue in Biopharmaceutical CDMO Business (2021–2026)

11.1.5 Lonza Recent Development

11.2 Catalent

11.2.1 Catalent Company Details

11.2.2 Catalent Business Overview

11.2.3 Catalent Biopharmaceutical CDMO Introduction

11.2.4 Catalent Revenue in Biopharmaceutical CDMO Business (2021–2026)

11.2.5 Catalent Recent Development

11.3 Samsung Biologics

11.3.1 Samsung Biologics Company Details

11.3.2 Samsung Biologics Business Overview

11.3.3 Samsung Biologics Biopharmaceutical CDMO Introduction

11.3.4 Samsung Biologics Revenue in Biopharmaceutical CDMO Business (2021–2026)

11.3.5 Samsung Biologics Recent Development

11.4 FUJIFILM Diosynth Biotechnologies

11.4.1 FUJIFILM Diosynth Biotechnologies Company Details

11.4.2 FUJIFILM Diosynth Biotechnologies Business Overview

11.4.3 FUJIFILM Diosynth Biotechnologies Biopharmaceutical CDMO Introduction

11.4.4 FUJIFILM Diosynth Biotechnologies Revenue in Biopharmaceutical CDMO Business (2021–2026)

11.4.5 FUJIFILM Diosynth Biotechnologies Recent Development

11.5 Boehringer Ingelheim

11.5.1 Boehringer Ingelheim Company Details

11.5.2 Boehringer Ingelheim Business Overview

11.5.3 Boehringer Ingelheim Biopharmaceutical CDMO Introduction

11.5.4 Boehringer Ingelheim Revenue in Biopharmaceutical CDMO Business (2021–2026)

11.5.5 Boehringer Ingelheim Recent Development

11.6 WuXi AppTech

11.6.1 WuXi AppTech Company Details

11.6.2 WuXi AppTech Business Overview

11.6.3 WuXi AppTech Biopharmaceutical CDMO Introduction

11.6.4 WuXi AppTech Revenue in Biopharmaceutical CDMO Business (2021–2026)

11.6.5 WuXi AppTech Recent Development

11.7 Recipharm

11.7.1 Recipharm Company Details

11.7.2 Recipharm Business Overview

11.7.3 Recipharm Biopharmaceutical CDMO Introduction

11.7.4 Recipharm Revenue in Biopharmaceutical CDMO Business (2021–2026)

11.7.5 Recipharm Recent Development

11.8 Thermo Fisher Scientific

11.8.1 Thermo Fisher Scientific Company Details

11.8.2 Thermo Fisher Scientific Business Overview

11.8.3 Thermo Fisher Scientific Biopharmaceutical CDMO Introduction

11.8.4 Thermo Fisher Scientific Revenue in Biopharmaceutical CDMO Business (2021–2026)

11.8.5 Thermo Fisher Scientific Recent Development

11.9 AGC Biologics

11.9.1 AGC Biologics Company Details

11.9.2 AGC Biologics Business Overview

11.9.3 AGC Biologics Biopharmaceutical CDMO Introduction

11.9.4 AGC Biologics Revenue in Biopharmaceutical CDMO Business (2021–2026)

11.9.5 AGC Biologics Recent Development

11.10 Rentschler Biopharma

11.10.1 Rentschler Biopharma Company Details

11.10.2 Rentschler Biopharma Business Overview

11.10.3 Rentschler Biopharma Biopharmaceutical CDMO Introduction

11.10.4 Rentschler Biopharma Revenue in Biopharmaceutical CDMO Business (2021–2026)

11.10.5 Rentschler Biopharma Recent Development

11.11 KBI Biopharma

11.11.1 KBI Biopharma Company Details

11.11.2 KBI Biopharma Business Overview

11.11.3 KBI Biopharma Biopharmaceutical CDMO Introduction

11.11.4 KBI Biopharma Revenue in Biopharmaceutical CDMO Business (2021–2026)

11.11.5 KBI Biopharma Recent Development

11.12 Siegfried

11.12.1 Siegfried Company Details

11.12.2 Siegfried Business Overview

11.12.3 Siegfried Biopharmaceutical CDMO Introduction

11.12.4 Siegfried Revenue in Biopharmaceutical CDMO Business (2021–2026)

11.12.5 Siegfried Recent Development

11.13 Aenova Group

11.13.1 Aenova Group Company Details

11.13.2 Aenova Group Business Overview

11.13.3 Aenova Group Biopharmaceutical CDMO Introduction

11.13.4 Aenova Group Revenue in Biopharmaceutical CDMO Business (2021–2026)

11.13.5 Aenova Group Recent Development

11.14 GenScript

11.14.1 GenScript Company Details

11.14.2 GenScript Business Overview

11.14.3 GenScript Biopharmaceutical CDMO Introduction

11.14.4 GenScript Revenue in Biopharmaceutical CDMO Business (2021–2026)

11.14.5 GenScript Recent Development

11.15 ProBioGen

11.15.1 ProBioGen Company Details

11.15.2 ProBioGen Business Overview

11.15.3 ProBioGen Biopharmaceutical CDMO Introduction

11.15.4 ProBioGen Revenue in Biopharmaceutical CDMO Business (2021–2026)

11.15.5 ProBioGen Recent Development

11.16 Northway Biotech

11.16.1 Northway Biotech Company Details

11.16.2 Northway Biotech Business Overview

11.16.3 Northway Biotech Biopharmaceutical CDMO Introduction

11.16.4 Northway Biotech Revenue in Biopharmaceutical CDMO Business (2021–2026)

11.16.5 Northway Biotech Recent Development

11.17 3P Biopharmaceuticals

11.17.1 3P Biopharmaceuticals Company Details

11.17.2 3P Biopharmaceuticals Business Overview

11.17.3 3P Biopharmaceuticals Biopharmaceutical CDMO Introduction

11.17.4 3P Biopharmaceuticals Revenue in Biopharmaceutical CDMO Business (2021–2026)

11.17.5 3P Biopharmaceuticals Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Recipharm

Samsung Biologics

Siegfried

Aenova Group

GenScript

ProBioGen

KBI Biopharma

3P Biopharmaceuticals

Rentschler Biopharma

Northway Biotech

Boehringer Ingelheim

Lonza

Catalent

FUJIFILM Diosynth Biotechnologies

WuXi AppTech

Thermo Fisher Scientific

AGC Biologics

List of Tables

Table 1. Global Biopharmaceutical CDMO Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of Cell and Gene Therapies

Table 3. Key Players of Antibodies

Table 4. Key Players of Vaccines

Table 5. Key Players of Other

Table 6. Global Biopharmaceutical CDMO Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 7. Global Biopharmaceutical CDMO Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 8. Global Biopharmaceutical CDMO Market Size by Region (US$ Million), 2021–2026

Table 9. Global Biopharmaceutical CDMO Market Share by Region (2021–2026)

Table 10. Global Biopharmaceutical CDMO Forecasted Market Size by Region (US$ Million), 2027–2032

Table 11. Global Biopharmaceutical CDMO Market Share by Region (2027–2032)

Table 12. Biopharmaceutical CDMO Market Trends

Table 13. Biopharmaceutical CDMO Market Drivers

Table 14. Biopharmaceutical CDMO Market Challenges

Table 15. Biopharmaceutical CDMO Market Restraints

Table 16. Global Biopharmaceutical CDMO Revenue by Players (US$ Million), 2021–2026

Table 17. Global Biopharmaceutical CDMO Market Share by Players (2021–2026)

Table 18. Global Top Biopharmaceutical CDMO Players by Tier (Tier 1, Tier 2, and Tier 3), based on Biopharmaceutical CDMO Revenue, 2025

Table 19. Ranking of Global Top Biopharmaceutical CDMO Companies by Revenue (US$ Million) in 2025

Table 20. Global 5 Largest Players Market Share by Biopharmaceutical CDMO Revenue (CR5 and HHI), 2021–2026

Table 21. Global Key Players of Biopharmaceutical CDMO, Headquarters and Area Served

Table 22. Global Key Players of Biopharmaceutical CDMO, Products and Applications

Table 23. Global Key Players of Biopharmaceutical CDMO, Date of General Availability (GA)

Table 24. Mergers and Acquisitions, Expansion Plans

Table 25. Global Biopharmaceutical CDMO Market Size by Type (US$ Million), 2021–2026

Table 26. Global Biopharmaceutical CDMO Revenue Market Share by Type (2021–2026)

Table 27. Global Biopharmaceutical CDMO Forecasted Market Size by Type (US$ Million), 2027–2032

Table 28. Global Biopharmaceutical CDMO Revenue Market Share by Type (2027–2032)

Table 29. Global Biopharmaceutical CDMO Market Size by Application (US$ Million), 2021–2026

Table 30. Global Biopharmaceutical CDMO Revenue Market Share by Application (2021–2026)

Table 31. Global Biopharmaceutical CDMO Forecasted Market Size by Application (US$ Million), 2027–2032

Table 32. Global Biopharmaceutical CDMO Revenue Market Share by Application (2027–2032)

Table 33. North America Biopharmaceutical CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 34. North America Biopharmaceutical CDMO Market Size by Country (US$ Million), 2021–2026

Table 35. North America Biopharmaceutical CDMO Market Size by Country (US$ Million), 2027–2032

Table 36. Europe Biopharmaceutical CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 37. Europe Biopharmaceutical CDMO Market Size by Country (US$ Million), 2021–2026

Table 38. Europe Biopharmaceutical CDMO Market Size by Country (US$ Million), 2027–2032

Table 39. Asia-Pacific Biopharmaceutical CDMO Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 40. Asia-Pacific Biopharmaceutical CDMO Market Size by Region (US$ Million), 2021–2026

Table 41. Asia-Pacific Biopharmaceutical CDMO Market Size by Region (US$ Million), 2027–2032

Table 42. Latin America Biopharmaceutical CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 43. Latin America Biopharmaceutical CDMO Market Size by Country (US$ Million), 2021–2026

Table 44. Latin America Biopharmaceutical CDMO Market Size by Country (US$ Million), 2027–2032

Table 45. Middle East & Africa Biopharmaceutical CDMO Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 46. Middle East & Africa Biopharmaceutical CDMO Market Size by Country (US$ Million), 2021–2026

Table 47. Middle East & Africa Biopharmaceutical CDMO Market Size by Country (US$ Million), 2027–2032

Table 48. Lonza Company Details

Table 49. Lonza Business Overview

Table 50. Lonza Biopharmaceutical CDMO Product

Table 51. Lonza Revenue in Biopharmaceutical CDMO Business (US$ Million), 2021–2026

Table 52. Lonza Recent Development

Table 53. Catalent Company Details

Table 54. Catalent Business Overview

Table 55. Catalent Biopharmaceutical CDMO Product

Table 56. Catalent Revenue in Biopharmaceutical CDMO Business (US$ Million), 2021–2026

Table 57. Catalent Recent Development

Table 58. Samsung Biologics Company Details

Table 59. Samsung Biologics Business Overview

Table 60. Samsung Biologics Biopharmaceutical CDMO Product

Table 61. Samsung Biologics Revenue in Biopharmaceutical CDMO Business (US$ Million), 2021–2026

Table 62. Samsung Biologics Recent Development

Table 63. FUJIFILM Diosynth Biotechnologies Company Details

Table 64. FUJIFILM Diosynth Biotechnologies Business Overview

Table 65. FUJIFILM Diosynth Biotechnologies Biopharmaceutical CDMO Product

Table 66. FUJIFILM Diosynth Biotechnologies Revenue in Biopharmaceutical CDMO Business (US$ Million), 2021–2026

Table 67. FUJIFILM Diosynth Biotechnologies Recent Development

Table 68. Boehringer Ingelheim Company Details

Table 69. Boehringer Ingelheim Business Overview

Table 70. Boehringer Ingelheim Biopharmaceutical CDMO Product

Table 71. Boehringer Ingelheim Revenue in Biopharmaceutical CDMO Business (US$ Million), 2021–2026

Table 72. Boehringer Ingelheim Recent Development

Table 73. WuXi AppTech Company Details

Table 74. WuXi AppTech Business Overview

Table 75. WuXi AppTech Biopharmaceutical CDMO Product

Table 76. WuXi AppTech Revenue in Biopharmaceutical CDMO Business (US$ Million), 2021–2026

Table 77. WuXi AppTech Recent Development

Table 78. Recipharm Company Details

Table 79. Recipharm Business Overview

Table 80. Recipharm Biopharmaceutical CDMO Product

Table 81. Recipharm Revenue in Biopharmaceutical CDMO Business (US$ Million), 2021–2026

Table 82. Recipharm Recent Development

Table 83. Thermo Fisher Scientific Company Details

Table 84. Thermo Fisher Scientific Business Overview

Table 85. Thermo Fisher Scientific Biopharmaceutical CDMO Product

Table 86. Thermo Fisher Scientific Revenue in Biopharmaceutical CDMO Business (US$ Million), 2021–2026

Table 87. Thermo Fisher Scientific Recent Development

Table 88. AGC Biologics Company Details

Table 89. AGC Biologics Business Overview

Table 90. AGC Biologics Biopharmaceutical CDMO Product

Table 91. AGC Biologics Revenue in Biopharmaceutical CDMO Business (US$ Million), 2021–2026

Table 92. AGC Biologics Recent Development

Table 93. Rentschler Biopharma Company Details

Table 94. Rentschler Biopharma Business Overview

Table 95. Rentschler Biopharma Biopharmaceutical CDMO Product

Table 96. Rentschler Biopharma Revenue in Biopharmaceutical CDMO Business (US$ Million), 2021–2026

Table 97. Rentschler Biopharma Recent Development

Table 98. KBI Biopharma Company Details

Table 99. KBI Biopharma Business Overview

Table 100. KBI Biopharma Biopharmaceutical CDMO Product

Table 101. KBI Biopharma Revenue in Biopharmaceutical CDMO Business (US$ Million), 2021–2026

Table 102. KBI Biopharma Recent Development

Table 103. Siegfried Company Details

Table 104. Siegfried Business Overview

Table 105. Siegfried Biopharmaceutical CDMO Product

Table 106. Siegfried Revenue in Biopharmaceutical CDMO Business (US$ Million), 2021–2026

Table 107. Siegfried Recent Development

Table 108. Aenova Group Company Details

Table 109. Aenova Group Business Overview

Table 110. Aenova Group Biopharmaceutical CDMO Product

Table 111. Aenova Group Revenue in Biopharmaceutical CDMO Business (US$ Million), 2021–2026

Table 112. Aenova Group Recent Development

Table 113. GenScript Company Details

Table 114. GenScript Business Overview

Table 115. GenScript Biopharmaceutical CDMO Product

Table 116. GenScript Revenue in Biopharmaceutical CDMO Business (US$ Million), 2021–2026

Table 117. GenScript Recent Development

Table 118. ProBioGen Company Details

Table 119. ProBioGen Business Overview

Table 120. ProBioGen Biopharmaceutical CDMO Product

Table 121. ProBioGen Revenue in Biopharmaceutical CDMO Business (US$ Million), 2021–2026

Table 122. ProBioGen Recent Development

Table 123. Northway Biotech Company Details

Table 124. Northway Biotech Business Overview

Table 125. Northway Biotech Biopharmaceutical CDMO Product

Table 126. Northway Biotech Revenue in Biopharmaceutical CDMO Business (US$ Million), 2021–2026

Table 127. Northway Biotech Recent Development

Table 128. 3P Biopharmaceuticals Company Details

Table 129. 3P Biopharmaceuticals Business Overview

Table 130. 3P Biopharmaceuticals Biopharmaceutical CDMO Product

Table 131. 3P Biopharmaceuticals Revenue in Biopharmaceutical CDMO Business (US$ Million), 2021–2026

Table 132. 3P Biopharmaceuticals Recent Development

Table 133. Research Programs/Design for This Report

Table 134. Key Data Information from Secondary Sources

Table 135. Key Data Information from Primary Sources

Table 136. Authors List of This Report

List of Figures

Figure 1. Biopharmaceutical CDMO Picture

Figure 2. Global Biopharmaceutical CDMO Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global Biopharmaceutical CDMO Market Share by Type: 2025 vs 2032

Figure 4. Cell and Gene Therapies Features

Figure 5. Antibodies Features

Figure 6. Vaccines Features

Figure 7. Other Features

Figure 8. Global Biopharmaceutical CDMO Market Size by Application (US$ Million), 2021–2032

Figure 9. Global Biopharmaceutical CDMO Market Share by Application: 2025 vs 2032

Figure 10. SMBs Case Studies

Figure 11. Large Companies Case Studies

Figure 12. Biopharmaceutical CDMO Report Years Considered

Figure 13. Global Biopharmaceutical CDMO Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 14. Global Biopharmaceutical CDMO Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 15. Global Biopharmaceutical CDMO Market Share by Region: 2025 vs 2032

Figure 16. Global Biopharmaceutical CDMO Market Share by Players in 2025

Figure 17. Global Biopharmaceutical CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 18. The Top 10 and 5 Players Market Share by Biopharmaceutical CDMO Revenue in 2025

Figure 19. North America Biopharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 20. North America Biopharmaceutical CDMO Market Share by Country (2021–2032)

Figure 21. United States Biopharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 22. Canada Biopharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 23. Europe Biopharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 24. Europe Biopharmaceutical CDMO Market Share by Country (2021–2032)

Figure 25. Germany Biopharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 26. France Biopharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 27. U.K. Biopharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 28. Italy Biopharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 29. Russia Biopharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 30. Ireland Biopharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 31. Asia-Pacific Biopharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 32. Asia-Pacific Biopharmaceutical CDMO Market Share by Region (2021–2032)

Figure 33. China Biopharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 34. Japan Biopharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. South Korea Biopharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 36. Southeast Asia Biopharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. India Biopharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. Australia & New Zealand Biopharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Latin America Biopharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 40. Latin America Biopharmaceutical CDMO Market Share by Country (2021–2032)

Figure 41. Mexico Biopharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 42. Brazil Biopharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 43. Middle East & Africa Biopharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 44. Middle East & Africa Biopharmaceutical CDMO Market Share by Country (2021–2032)

Figure 45. Israel Biopharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 46. Saudi Arabia Biopharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. UAE Biopharmaceutical CDMO Market Size YoY Growth (US$ Million), 2021–2032

Figure 48. Lonza Revenue Growth Rate in Biopharmaceutical CDMO Business (2021–2026)

Figure 49. Catalent Revenue Growth Rate in Biopharmaceutical CDMO Business (2021–2026)

Figure 50. Samsung Biologics Revenue Growth Rate in Biopharmaceutical CDMO Business (2021–2026)

Figure 51. FUJIFILM Diosynth Biotechnologies Revenue Growth Rate in Biopharmaceutical CDMO Business (2021–2026)

Figure 52. Boehringer Ingelheim Revenue Growth Rate in Biopharmaceutical CDMO Business (2021–2026)

Figure 53. WuXi AppTech Revenue Growth Rate in Biopharmaceutical CDMO Business (2021–2026)

Figure 54. Recipharm Revenue Growth Rate in Biopharmaceutical CDMO Business (2021–2026)

Figure 55. Thermo Fisher Scientific Revenue Growth Rate in Biopharmaceutical CDMO Business (2021–2026)

Figure 56. AGC Biologics Revenue Growth Rate in Biopharmaceutical CDMO Business (2021–2026)

Figure 57. Rentschler Biopharma Revenue Growth Rate in Biopharmaceutical CDMO Business (2021–2026)

Figure 58. KBI Biopharma Revenue Growth Rate in Biopharmaceutical CDMO Business (2021–2026)

Figure 59. Siegfried Revenue Growth Rate in Biopharmaceutical CDMO Business (2021–2026)

Figure 60. Aenova Group Revenue Growth Rate in Biopharmaceutical CDMO Business (2021–2026)

Figure 61. GenScript Revenue Growth Rate in Biopharmaceutical CDMO Business (2021–2026)

Figure 62. ProBioGen Revenue Growth Rate in Biopharmaceutical CDMO Business (2021–2026)

Figure 63. Northway Biotech Revenue Growth Rate in Biopharmaceutical CDMO Business (2021–2026)

Figure 64. 3P Biopharmaceuticals Revenue Growth Rate in Biopharmaceutical CDMO Business (2021–2026)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Bio Contract Development and Manufacturing Organizations CDMOs Market Insights Forecast to 2030

Global Cell and Gene Therapy CDMO Services Market Research Report 2024

Biologics CDMO Market

Global Full Service CDMO Market Research Report 2024

Global Chemical CDMO Market Research Report 2024

Global Pharmaceutical Contract Development and Manufacturing Organization Market Research Report 2025

Global Contract Dose Manufacturing Market Insights Forecast to 2030

Global Cell Therapy CDMO Services Market Research Report 2025

Global Pharmaceutical CDMO Market Research Report 2025

Pharmaceutical CMO and CDMO Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Small Molecule Drug CDMO Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Biopharmaceutical and Bio CDMO Market Research Report 2024

Global Biological Drug CDMO Market Research Report 2024

Global Biologics CDMO Services Market Research Report 2024

Pharmaceutical CDMO Solution Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Viral Vector Manufacturing CDMO Services Market Research Report 2024

Global Plasmid DNA CDMO Service Market Research Report 2024

Global Antibody Drug CDMO Service Market Research Report 2024

Global Microbiome CDMO Market Research Report 2024

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions